Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: a multi-institutional study

Abstract Background There is little data on the outcome of cabazitaxel (CBZ) treatment of elderly patients with castration-resistant prostate cancer (CRPC). This study assessed the efficacy and safety of CBZ chemotherapy in CRPC patients aged 75 or older in multi-institutional study. Methods We retrospectively reviewed the 74 patients with CRPC treated with CBZ enrolled in 10 institutions. Clinicopathological backgrounds, prognosis including PSA decline, time to treatment failure, progression-free survival, overall survival, and safety profiles were compared between younger ( Results In total, 74 patients were enrolled; 50 patients were under the age of75 years and 24 were ≥75 years old. Clinicopathological characteristics were comparable between younger and elder patients, with the exception of serum albumin values at the time of CBZ treatment. Median PSA decline in younger and elder men were –8.8% and –32.3% from baseline, respectively. Median time to treatment failure, progression free survival, and overall survival for younger and elder men were 0.24 and 0.33 years, 0.23 and 0.43 years, and 0.69 and 1.17 years, respectively. Additionally, safety profiles were comparable between younger and elder patients. Conclusions This multi-institutional study suggests that CRPC patients aged 75 or older eligible for CBZ treatment can be treated safely and with non-inferior efficacy compared with those under 75 years.